Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4850135
Max Phase: Preclinical
Molecular Formula: C44H43FN8O5
Molecular Weight: 782.88
Molecule Type: Unknown
Associated Items:
ID: ALA4850135
Max Phase: Preclinical
Molecular Formula: C44H43FN8O5
Molecular Weight: 782.88
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCC(=O)Nc1cc(-c2ccc(N3CCN(C(=O)c4cc(Cc5n[nH]c(=O)c6ccccc56)ccc4F)CC3)nc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C
Standard InChI: InChI=1S/C44H43FN8O5/c1-5-40(54)49-37-22-30(21-33(27(37)4)41(55)47-24-35-25(2)18-26(3)48-42(35)56)29-11-13-39(46-23-29)52-14-16-53(17-15-52)44(58)34-19-28(10-12-36(34)45)20-38-31-8-6-7-9-32(31)43(57)51-50-38/h6-13,18-19,21-23H,5,14-17,20,24H2,1-4H3,(H,47,55)(H,48,56)(H,49,54)(H,51,57)
Standard InChI Key: YLEIVKBLZYEPPM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 782.88 | Molecular Weight (Monoisotopic): 782.3340 | AlogP: 5.57 | #Rotatable Bonds: 10 |
Polar Surface Area: 173.25 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.95 | CX Basic pKa: 6.91 | CX LogP: 4.49 | CX LogD: 4.48 |
Aromatic Rings: 6 | Heavy Atoms: 58 | QED Weighted: 0.14 | Np Likeness Score: -1.75 |
1. Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, Kong L, Wang X.. (2021) Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA., 64 (17.0): [PMID:34455779] [10.1021/acs.jmedchem.1c00567] |
Source(1):